Correction: Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma

Suliman Boulos; Min Chul Park; Marian Zeibak; Shen Yun Foo; Yoon Kyung Jeon; Young Tae Kim; Alex Motzik; Sagi Tshori; Tamar Hamburger; Sunghoon Kim; Hovav Nechushtan; Ehud Razin

doi:10.18632/oncotarget.26387

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma

PDF | How to cite

Oncotarget. 2018; 9:36250-36250. https://doi.org/10.18632/oncotarget.26387

Metrics: PDF 1278 views | ?

Suliman Boulos^1,*, Min Chul Park^2,*, Marian Zeibak³, Shen Yun Foo⁴, Yoon Kyung Jeon⁵, Young Tae Kim⁶, Alex Motzik³, Sagi Tshori⁷, Tamar Hamburger⁸, Sunghoon Kim², Hovav Nechushtan¹ and Ehud Razin^3,4

¹ Department of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
² Medicinal Bioconvergence Research Center, Seoul National University, Seoul, Korea
³ Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel
⁴ NUS-HUJ-CREATE Cellular & Molecular Mechanisms of Inflammation Program, Department of Microbiology and Immunology, National University of Singapore, Singapore
⁵ Department of Pathology, Seoul National University Hospital, Seoul, Korea
⁶ Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, Korea
⁷ Kaplan Medical Center, Rehovot, Israel
⁸ Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
^* These authors have contributed equally to this work

Published: November 16, 2018

This article has been corrected: The correct title for figure 5 is given below:

Figure 5: Subgroup analysis of nuclear P207 LysRS according to Lymph nodes positivity. Disease free survival of wild-type EGFR patients with (positive) or without (negative) cytosolic (A) and nuclear (B) LysRS. Disease free survival of mutated EGFR patients with (positive) or without (negative) cytosolic (C) and nuclear (D) LysRS.

Original article: Oncotarget. 2017; 8:65186-65198. DOI: https://doi.org/10.18632/oncotarget.18053.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26387

Publication Alerts

Corrections:

Correction: Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma